Introduction
Polycystic kidney diseases (PKD) are a heterogeneous group of disorders inherited either as autosomal dominant (ADPKD) or autosomal recessive (ARPKD) traits (Calvet, 1998; Gabow, 1993 for reviews) . The autosomal dominant form of PKD is most common; it results in large cysts lined with epithelium that can grow from all parts of the nephron. Although the kidney is the most severely aected organ, cysts are frequently found in the liver and pancreas (Calvet, 1998) . ADPKD is caused by mutations of at least three genes. Mutations in the PKD1 gene account for 85% of the ADPKD, while mutations in the PKD2 gene account for 10% of the disease. The PKD3 gene has not yet been identi®ed (Calvet, 1998) . The structures of the PKD1 and PKD2 genes have recently been determined, but the exact function of the polycystins encoded by these PKD genes is still poorly understood. Polycystin-1, the PKD-1 gene product, is predicted to contain a large extracytoplasmic amino-terminal domain, multiple transmembrane domains and a small cytoplasmic carboxy-terminus domain. The structure of the polycystin-1 domains suggests that this protein is involved in cell ± cell or cell ± matrix interactions (Hughes et al., 1995) . Polycystin-2, the PKD-2 gene product, is predicted to encode a transmembrane protein with both the N-and C-terminal domains in the cytosol (Mochizuki et al., 1996) . The fact that mutations in either the PKD1 or PKD2 genes cause almost indistinguishable clinical symptoms and that both proteins can interact directly via their carboxyterminal regions has led to the hypothesis that these two proteins act together to form a macromolecular complex at the cytoplasmic membrane, called the polycystin complex, which might control dierentiation of renal epithelial cells (Qian et al., 1997; Tsiokas et al., 1997) . The signaling pathway triggered by the polycystin complex is not yet known, but it appears to be conserved. Recent data obtained in the nematode worm Caenorhabditis elegans suggest that orthologues of polycystins PKD1 and PKD2 act together in a signal transduction pathway in sensory neurons (Barr and Sternberg, 1999) . However, although the genetics of ADPKD is now much clearer, the pathogenesis of the polycystic kidney disease remains largely obscure. Several studies strongly suggest that the polycystin complex is linked to the b-catenin signaling pathway, which is implicated in development and deregulated in several cancers (Huan and van Adelsberg, 1999; Kim et al., 1999) . b-catenin is a multifunctional protein involved in cell adhesion, as part of the cadherincatenin complexes, and in the control of cell proliferation, as part of the Wnt signaling pathway (Polakis, 2000, for review) . In the absence of activation of the Wnt pathway, b-catenin is phosphorylated in a multi-protein complex by glycogen synthase kinase 3b (GSK3b kinase) and then targeted for ubiquitination and degradation by the proteasome. Activation of the Wnt signaling involves the inhibition of GSK3b activity and the subsequent postranslational stabilization of the soluble b-catenin, leading to its accumulation in the cytoplasm and nucleus. In the nucleus, b-catenin interacts with members of the LEF ± TCF family of transcription factors and regulates the expression of genes thought to be involved in the control of cell proliferation and apoptosis (Polakis, 2000) . Inappropriate activation of this pathway has recently been described in several human cancers; it is responsible for initiating most colon cancers and is involved in a growing number of cancers (Polakis, 2000) .
Our recent observation that the expression of an activated b-catenin mutant in transgenic mice exhibited numerous kidney cysts (Romagnolo et al., 1999) is another link between PKD and b-catenin signaling. We have now further analysed the phenotype developed by transgenic mice overexpressing an oncogenic mutant bcatenin transgene in kidneys. These mice rapidly developed severe polycystic lesions aecting all parts of the nephron during the ®rst 3 weeks after birth. Cyst formation was associated with an increase in cell proliferation and apoptosis. The phenotype of these mice mimicks the human ADPKD phenotype. Thus these results provide experimental genetic evidence that activation of the Wnt/b-catenin signaling pathway causes polycystic kidney disease and suggest that dysregulation of the Wnt/b-catenin signaling is involved in the pathogenesis of polycystic kidney disease.
Results

Expression of the DN131-b-catenin mutant in kidneys of transgenic mice
The expression of an activated b-catenin mutant was targeted to the kidney by using a chimeric construct containing the regulatory sequences of the calbindin-D9K gene and the enhancer of the aldolase B gene (Figure 1a) . The b-catenin mutant was a NH2-terminal truncation mutant (DN131b-catenin) that has lost both the GSK3b phosphorylation site involved in the control of the stability of the protein and the binding site for a-catenin necessary for the adhesive properties of b-catenin (Figure 1a) . The DN131b-catenin mutant is responsible for a constitutive activation of the Wnt/ b-catenin pathway (Barth et al., 1999) . We previously observed that the EAB/9K ± DN131b-catenin construct is prone to a strong positional eect (Cadoret et al., 2001; Romagnolo et al., 1999) . Most of the founders expressing the transgene at a high level in the intestine, kidney and liver revealed signs of distress and several were found dead precluding any analysis. Although the exact cause(s) of the death were not known, it probably resulted from the sum of the metabolic dysregulations observed both in kidney and in the liver (this study, Cadoret et al., 2001; Romagnolo et al., 1999) . Therefore the founders were analysed between the third and fourth weeks of age (Table 1) .
The expression of the transgene in the kidney was analysed by Northern blotting and quanti®ed by realtime reverse transcription-PCR assay ( Figure 1b and Table 1 ). All the four transgenic founders that develop severe PKD expressed high level of DN131b-catenin mutant, 1.3 ± 4.7-fold higher than that of the endogenous b-catenin gene. The E313 founder that developed microcystic lesions had a mild expression of the transgene (60.5-fold) as compared to that of the endogenous gene. No kidney abnormality was observed in two transgenic founders that express the transgene at a very low level, (60.1-and 0.02-fold that of the endogenous gene) ( Table 1 ). Only one founder that express the transgene at a relatively high level, 61.2-fold that of the endogenous gene, did not develop PKD. Such variability probably resulted from the noninbred genetic background, since founders were obtained on a mixed C57BL6/DBA genetic background. Alltogether, the results from analysis of eight independent founders showed a clear correlation between the amount of the DN131b-catenin mutant in kidneys and the development of renal cysts. Thus these results indicate that the polycystic kidney disease developed in the DN131b-catenin transgenic mice is associated with, and probably due to, the synthesis of large amounts of the oncogenic mutant form of bcatenin. Renal disorders in DN131-b-catenin transgenic mice High expression of activated b-catenin mutant in the kidneys of transgenic founders led to a dramatic distortion of the renal cortical and medullary architecture (Figure 2a ). Histological analysis of kidney sections revealed bilateral multifocal cystic formations in both the cortical and medullary zones of the kidney (Figure 2c ± e). There were glomerular and tubular cysts of varying sizes in the kidney cortex (Figure 2c,f) . The inner medulla and papilla mass was substantially reduced and replaced by a large central cyst in most of the founders actively expressing the transgene (Figure 2a ,e). There were no cystic lesion in nontransgenic control mice of the same age ( Figure  2b,d ). The development of cystic lesions in all parts of the nephron is in accordance with the expected speci®city of transgene expression resulting from the regulatory sequences in the chimeric construct. The enhancers of the aldolase B and the calbindin-D9K genes can target gene expression to the proximal and distal regions of the kidney, respectively (Saez and Slebe, 2000) (Christakos et al., 1989) .
To de®ne more precisely the origin of the renal cysts formed in DN131-b-catenin transgenic mice immunohistochemical studies were performed using markers of proximal and distal-collecting tubules. Three population of cysts were found. A population stained positively with the antivillin antibody consistent with a proximal tubular origin ( Figure  3a) . Analysis of semi-thin sections revealed the presence of apical brush border, a typical feature of normal proximal tubule cells (Figure 3b) . A second population stained positively for the lectin DBA consistent with an origin from the collecting ducts ( Figure 3c ). Finaly, a third population stained positively with the anticalbindin-D9K antibody consistent with a distal-collecting duct origin ( Figure 3d ).
These data indicated thus that the synthesis of an activated b-catenin mutant causes the formation of renal cysts originating from all the parts of the nephron, including glomeruli, proximal and distal tubules and collecting ducts.
Persistence of a nephrogenic zone in kidney of DN131-b-catenin transgenic mice
Nephrogenesis is not complete at birth in rodents, in contrast to human. Nephrons continue to develop from a nephrogenic zone at the periphery of the kidney during the ®rst weeks of life (Ekblom, 1992) . However, we observed in the cortex a number of immature tubules with the S-shape-like structure in all the DN131-b-catenin transgenic mice with severe kidney lesions. These immature regions were not detected in 3-week-old normal mice (Figure 2g ,h). Thus, this result suggests that the expression of an activated b-catenin mutant gene in the kidney is associated with defective maturation of this organ.
Increased cell proliferation in the kidneys of DN131-b-catenin transgenic mice
Alterations in cell proliferation and apoptosis have been proposed as important factors in the development of renal cysts in polycystic kidney disease (Gabow, 1993) . In vivo, the potential oncogenic role of the activated b-catenin mutants is responsible for an increase in cell proliferation in various tissues, such as the intestine, liver, and skin (Cadoret et al., 2001; Gat et al., 1998; Harada et al., 1999; Romagnolo et al., 1999) . This particular features of b-catenin mutants led us to analyse the cell proliferation and death that accompany the development of cysts in kidneys of DN131-b-catenin transgenic mice. Numerous mitotic and apoptotic Figures were observed in epithelial cells from non-dilated tubules and cysts from DN131-b-catenin kidneys (Figure 2i ,j). Apotosis was con®rmed by TUNEL analysis (Figure 2k ). The degree of cell proliferation was analysed using an antibody against Ki-67, a nuclear non-histone protein present only in cycling cells (Schluter et al., 1993) . Ki-67 positive cells were detected in the glomerulus and epithelium of both dilated or non-dilated proximal and distal-collecting tubules (Figure 4) . Ki-67 cell staining was elevated and the epithelial cell proliferation index increased 4 ± 5-fold in the cortex and medulla of the kidneys of all the DN131-b-catenin transgenic mice having an abnormal kidney phenotype as compared to non-transgenic littermates (Figures 4 The E313 founder presented microcystic lesions
Polycystic disease in b-catenin transgenic mice S Saadi-Kheddouci et al and 5a). Analysis of the E313 trangenic founder, which developed only a few microcystic tubular lesions (see Table 1 ), revealed intense Ki-67 staining in the cortex and medulla that was similar to that observed in the other founders with multiple and severe cystic lesions (Figure 4c ± f). These data suggest that increased cell proliferation is an early phenomenom that preceeds cyst formation. There was also an increase in the number of apoptotic cells in the kidneys of the DN131-b-catenin transgenic mice bearing cysts (Figure 5b Thus, these results show that a high concentration of an oncogenic form of b-catenin in the kidney induce a deregulation in cell proliferation and apoptosis associated with the development of kidney cysts.
Analysis of c-myc and cyclin D1in DN131-b-catenin transgenic mice
Increased expression of the c-myc oncogene has been reported in cysts from human ADPKD (Lanoix et al., 1996) and in one mouse model of ARPKD (Cowley et al., 1987) . Because recent studies have implicated both c-myc and cyclin D1 as positive b-catenin target genes (He et al., 1998; Tetsu and McCormick, 1999) , we tested to see whether these genes were more active in the kidneys of the DN131b-catenin mutant transgenic mice. We used real-time reverse transcription-PCR assay (Figure 6a ) and Western blotting (Figure 6b) . Although an important variability between each kidney analysed was observed, both in transgenic mice and littermate controls, no signi®cant increase in the expression of the c-myc and cyclin D1 gene could be detected in the kidney of the DN131-b-catenin founders that developed renal polycystic disesase (Figure 6 ). The expression of these two genes in the kidneys of transgenic mice that developed PKD was not signi®cantly increased compared to either transgenic mice that did not develop cysts or non-transgenic mice ATPase pumps to the apical membrane in cystic cells has been described in human ADPKD and proposed to be responsible for driving¯uid into the cysts, and thus favouring the enlargement of the kidney cyst (Wilson et al., 1991) . However, these results have been questioned (Sullivan et al., 1998) . This led us to examine the cellular localization of the Na (Figure 7 ). In accordance with previous data, both in human disease and in another transgenic mouse model (Barisoni et al., 1995; Wilson et al., 1991) we observed that some cysts failed to stain with the anti-aNa ATPase is mislocated to the apical membrane in the cystic cells (Sullivan et al., 1998) .
Discussion
We have shown that the expression of a mutant form of the oncogenic b-catenin gene in the kidneys of transgenic mice leads to the early development of polycystic kidney lesions. These lesions aect all parts of the nephron and ressemble those of the human ADPKD phenotype. Our results are of interest in the light of the new data on the molecular genetics of polycystic kidney disease. Two genes, PKD1 and PKD2, have been characterized that are associated with mutations that cause ADPKD. Molecular genetic evidence suggests that the protein products of these two genes are part of a macromolecular structure at the cytoplasmic membrane, called the polycystin complex, that participates in a common signaling pathway (reviewed in Calvet, 1998) . The signaling pathway triggered by the polycystin complex is not yet known. Most of the PKD1 and PKD2 gene mutations identi®ed in aected ADPKD families appear to be loss of function mutations. Recent data strongly suggest that the cysts are formed by a tumor suppressor mechanism. Hence, somatic inactivation of the normal allele has been described (Koptides et al., 1999; Qian et al., 1996) . However, the molecular mechanism of the PKD disease is still debated since a persistent expression of either PKD1 or PKD2 gene has been described in human PKD1 and PKD2 cystic kidneys respectively Ward et al., 1996) .
It has been proposed that mutations in PKD1 and PKD2, which cause very similar kidney disease, may result in the disruption of the polycystin complex and the subsequent deregulation of the signal transduction controlled by the polycystins that are involved in the dierentiation of kidney epithelial cells (Qian et al., 1997; Tsiokas et al., 1997) . The strongest argument in favor of this hypothesis is that invalidation of these two genes in mice leads to the same phenotype. In both cases, the homozygous mice die during the perinatal period with massive enlarged cystic kidneys (Lu et al., 1997 , Wu et al., 2000 . The development of kidney is normal until embryonic day 14.5 (E14.5) and renal cysts begin to be formed on E15.5. These results indicate that the polycystins are not essential during early nephrogenesis, but are important for the late stage of maturation of the nephron and required for the terminal dierentiation of the epithelial cells (Wu et al., 2000; Lu et al., 1997) . Recent studies have led to the proposition that the b-catenin signaling pathway is one of the downstream eectors. First, polycystin-1 has been found in a complex containing E-cadherin and catenins (Huan and van Adelsberg, 1999) . Second, the carboxyl terminal tail of polycystin-1 protects cytoplasmic b-catenin from degradation by the proteasome and activates Wnt/b-catenin-dependent transcription in mamalian cells (Kim et al., 1999) . Lastly, the mice de®cient for the Bcl-2 gene (Bcl-2 7/7 ) manifest congenital renal hypoplasia and develop postnatally polycystic kidney disease (Sorenson et al., 1996) . Interestingly, the epithelial cells that form the cysts in the Bcl-2 7/7 mice contain b-catenin in their nuclei (Sorenson, 1999) . These results suggest that an aberrant b-catenin signaling pathway may be one of the cellular defects in PKD. Our results show that the synthesis of an oncogenic form of b-catenin in the kidney of transgenic mice leads to the development of cysts ressembling the human ADPKD phenotype is consistent with the involvement of the Wnt/b-catenin signaling system in the pathogenesis of ADPKD. These data also suggest that other genes encoding partners of the Wnt/b-catenin signaling pathway may be candidate loci for other forms of ADPKD, such as the form associated with the PKD3 locus. Since the development of the kidney cysts is clonal and seems to follow thè two-hits' mechanism, the candidate gene is likely to have a tumor suppressor function. However, the absence of polycystic kidney disease in patients with familial polyposis carrying an APC gene mutation suggests that the APC gene, a key tumor suppressor gene of the Wnt/b-catenin signaling pathway is not involved in PKD.
Several other animal models of polycystic kidney disease have been described in transgenic mice expressing oncogenes in their kidneys : the SV40 early region, c-myc, H-ras or growth factors like KGF. Similar phenotypes have been reported for mice carrying targeted mutations for genes involved in the control of apoptosis, such as Bcl-2 or AP-2, a transcription factor implicated in the control of mycinduced apoptosis (reviewed in Calvet, 1998) . As in our DN131-b-catenin mice, there is dysregulation of cell proliferation and apoptosis in these various models, supporting the view that abnormal proliferation and apoptosis of tubule epithelial cells is a primary event in the pathogenesis of polycystic diseases (Gabow, 1993; Grantham, 1996) . Constitutive activation of the Wnt/bcatenin pathway is expected to act through deregulation of target genes. Two of them have recently been described, the oncogene c-myc (He et al., 1998) , and the gene encoding cyclin D1 (Tetsu and McCormick, 1999) . However these two genes were not overexpressed in kidneys from DN131-b-catenin transgenic mice that developed PKD. Although a transient expression of these two genes not detected by our experimental approaches cannot be excluded, our results suggest that they are not likely involved in the increase in cell proliferation in response to the expression of an oncogenic form of b-catenin.
A defective maturation of the kidney is associated with the development of cystic lesions in DN131-bcatenin transgenic mice. Wnt signaling is known to be important for normal kidney development. Kidney development begins with the condensation of mesenchyme around the uteric bud in response to a signal from the ureter. Reciprocal interactions between the uteric bud and the mesenchyme lead to condensation of the metanephric mesenchyme, which then aggregates into pretubular clusters, and undergoes epithelialization to form renal tubules. Subsequent morphogenesis and dierentiation of the tubular epithelium lead to the establishment of a functional nephron (reviewed in Lechner and Dressler, 1997) . At least two Wnt members appear to play a role in kidney development: Wnt-11, expressed in the uteric bud at E10.5 could participate in the primary inductive process (Vainio et al., 1999) and Wnt-4, expressed later, is required for the epithelialization of the mesenchyme (Stark et al., 1994) . Polycystins are probably required for the dierentiation of the tubular epithelial cells to a mature state (Lu et al., 1997; Wu et al., 2000) . Our ®ndings, together with recent reports (Kim et al., 1999; , indicate that one of the downstream eectors of the polycystin signal transduction could be the b-catenin signaling. Therefore the Wnt/bcatenin signaling pathway might play a critical role in all steps of kidney morphogenesis: induction (Wnt-11), epithelialization (Wnt-4) and epithelial maturation (Polycystins). In the maturation phase, polycystins that appear to have tumor suppressor functions, should induce an inhibition of the Wnt/b-catenin signaling with the subsequent inhibition of cell proliferation to allow for the terminal dierentiation of the tubular epithelial cells. In addition to its role on cell proliferation, Wnt signaling also regulates the function of both actin and microtubule cytoskeletons (Peifer and Polakis, 2000) , key players for the establishement of epithelial cell polarity. Thus, by modulating the Wnt/b-catenin signaling pathway, polycystins may regulate cell proliferation, cell polarity and morphogenesis, all process that are aected in ADPKD. However, the mechanism involved in the regulation of the b-catenin pathway by the polycystins remains to be determined.
In conclusion, our study provides functional evidence that the activation of the Wnt/b-catenin pathway in the kidney leads to the development of PKD lesions that mimic those developed in human ADPKD patients. It thus oers new possibilities for understanding the pathogenesis and possible prevention of ADPKD, a prevalent human inherited disease.
Materials and methods
Transgenic mice
We used the DN131-b-catenin transgenic mice that was described previously (Romagnolo et al., 1999) . The transgene contains the promoter and the regulatory sequences of the calbindin-D9K gene (Romagnolo et al., 1996) linked to the enhancer fragment of the aldolase B enhancer (Gregori et al., 1998) that controls the expression of human N-terminaltruncated b-catenin mutant (Hulsken et al., 1994) . The transgene was microinjected into fertilized (C57/B16/DBA) F1 hybrid mouse eggs to generate the transgenic founders.
The transgenic founders were sacri®ed when moribund or between 3 ± 4 weeks of age in order to analyse founders of same age.
All studies using mice were approved by the French Institutional Animal Care and Use of the MinisteÁ re de l'Agriculture.
Northern blot analysis
Total RNA was harvested by Chomczynski methods (Chomczynski and Sacchi, 1987) . Northern blotting was conducted on agrarose gels containing 1.2% formaldehyde; 10 mg of total RNA was loaded in each lane. The RNA was transferred to Hybond N+ membranes (Amersham, Buckinghamshire, UK), prehybridized and hybridized with a 32 P dCTP-labeled cDNA probe for the human b-catenin gene (Hulsken et al., 1994) using standard protocols.
Real-time RT ± PCR
The theorical basis of real-time RT ± PCR has been described elsewhere (Bieche et al., 1999) . Quantitative values are obtained from the threshold cycle number (Ct) at which the increase in the signal associated with exponential growth of PCR products begins to be detected using PE Biosystems analysis software, according to the manufacturer's manuals.
We used the RPLP0 gene (also known as 36B4) encoding human acidic ribosomal phosphoprotein P0 as the endogenous RNA control (Laborda, 1991) , and each sample was normalized on the basis of its RPLP0 content. The relative expression of the target gene was also normalized to a calibrator consisting of a tissue sample among our tested series which contained the smallest amount of target gene mRNA. Results, expressed as the amount of target sample relative to the RPLP0 gene and the calibrator, were determined as follows, N=2 7(DCtsample7DCtcalibrator) , where the DCt values of the sample and calibrator were determined by subtracting the average Ct value of the sample and the calibrator from the average Ct value of the RPLP0 gene.
Primers for the RPLP0 and target genes were chosen with the assistance of the computer programs cDNA was synthesized as previously described (Romagnolo et al., 1996) and PCR reactions were performed using a ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems). PCR was performed using the SYBR 1 Green PCR Core Reagents kit (Perkin-Elmer Applied Biosystems). The thermal cycling conditions included an initial denaturation step at 958C for 10 min and 50 cycles at 958C for 15 s and 658C for 1 min. Experiments were performed with duplicates for each data point.
Histological studies, cell proliferation analysis and TdT TUNEL method Kidneys were ®xed in 4% (v/v) formalin, embedded in paran, and stained with hematoxylin and eosin. Tissue sections (5 mm) were examined and evaluated for histopathological abnormalities. Kidneys were also ®xed by immersion for 2 h in 2.5% glutaradehyde in 0.1 M cacodylate buer and embedded in Epon. Semi-thin sections (100 nm) from kidney cortex were stained with toluidine blue (0.5%).
Para®n-embedded sections were analysed by immunohistochemistry using the polyclonal anti-Ki-67 antibody (dilution, 1 : 400; Novocastra, Newcastle, UK) to estimate the degree of cell proliferation. Sections were depara®nized in xylene, hydrated in a graded alcohol series, washed in phosphate-buered saline (PBS), and incubated in PBS blocking buer (PBS containing 3% bovine serum albumin) for 30 min. Polyclonal anti-Ki 67 antibody was added, and the slides incubated at room temperature for 1 h.
The TdT-mediated dUTP-biotin nick end labeling (TdT TUNEL) method was used to identify apoptotic cells.
Para®n-embedded sections were deparanized in toluene, rehydrated in an ethanol series and digested with 0.05% pepsin in 100 mM HCL pH 2. The slides were then incubated with Bio 11 dUTP (5 nM, Sigma, Saint-Quentin, France) and TdT enzyme (Amersham, Buckinghamshire, UK) in buer containing 100 mM Na cacodylate, 1 mM cobalt chloride (pH 7.2).
The proliferative index was estimated by the number of tubule epithelial cells that were Ki-67 positive. Cells were counted in four random high-power ®eld sections (HPF) (magni®cation 6400) of the kidney outer cortex, inner cortex and medulla. The apoptotic index was determined by counting the number of apoptotic kidney cells in these zones in four random HPF of sections stained with hematoxylin and eosin (magni®cation 61000). In both cases, values are given as mean numbers of cells per surface area+s.e.mean from the E412, E29, E222, E187, E313 founders showing kidney lesions and four non-transgenic controls. A P value 50.05 was considered signi®cant.
Immunohistochemical studies
Immunohistochemical studies were also performed to identify the cellular origin of the kidney cysts. Formalin-®xed sections were stained with a mouse monoclonal anti-villin antibody (kindly gift by Dr S Robine, Institut Curie, France, dilution 1 : 500) to mark proximal tubules, with biotinylated Dolichos bi¯orus agglutinin (DBA, Vector, Burlingame, CA, dilution 1 : 100) to mark collecting duct cells and with a rabbit polyclonal anti-calbindin-D9K antibody (prepared with a CaBP9K-GST fusion protein, dilution 1 : 400) to label distal tubule cells. To analyse the cell distribution of the Na + ,K + ATPase an anti-a-Na + ,K + ATPase antibody (dilution 1 : 50, kindly provided by Dr M Kaplan, Yale University, New Haven, CT, USA) was used. The protocol was similar to those decribed above for the Ki-67 staining.
Western blots
Tissues were homogenized with a Polytron in Laemmli buer (1 : 10 w/v). Sample of total protein (100 mg) were separated by 10% SDS ± PAGE and transferred to a nitrocellulose membrane. Cyclin D1, c-myc and a-tubulin proteins were detected with monoclonal antibodies against mouse cyclin D1 (DCS6, 1 : 300, Dako, Denmark), mouse c-myc (9E10, 1 : 500, Santa Cruz Biotechnologies, Santa Cruz, CA, USA) and atubulin (Amersham, Buckinghamshire, UK). The signals were visualized with the ECL detection system.
